One of our all-time favorite fitness trackers, the Oura ring, is currently at its lowest price ever. Nab the third-generation version of our favorite smart ring in select styles and colors for just under $200. The editor-tested device is now more than $150 cheaper than the comparable Gen 4 iteration. AMAZON'S NEXT PRIME Day is
South African Motorists will be paying 1 c/l more for both grades of petrol from Wednesday morning, while diesel will fall by 21 c/l. This comes after the department of mineral resources and energy on Monday announced its monthly fuel price adjustments for September.They are as follows:Petrol (both 93 ULP and LRP): 1.00 c/l increase;Petrol (both…
The Competition Commission has released a new report based on its monitoring of food prices.A large number of complaints received under excessive pricing regulations during the lockdown, were related to basic food products in retail stores.The report says food prices are stabilising, but could be slow to come down. Nearly 20% of the complaints received under…
Sheriff Norman Chaffins said he believes his family contracted the virus during a trip to Wyoming and Montana at the end of June. LOUISVILLE, Ky. — Grayson County Sheriff Norman Chaffins has confirmed he and his family has tested positive for coronavirus. Chaffins shared his experience battling the virus in a lengthy Facebook post on Sunday.…
Published: October 30, 2026, 10:16 pm Several reports of children choking have led to an FDA warning against Once Upon A Time snacks. The warning covers all flavors, quantities, lots and dates of Once Upon A Farm Tractor Wheels Organic, Toddler Soft-Baked Bars. The FDA has received several reports that describe infants ages 1.5 to
The FDA has cleared the interleukin (IL)-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis (PsA) in adults. Sun Pharma announced the approval on October 30. “As an IL-23 inhibitor administered exclusively by a healthcare provider, Ilumya is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec.